多靶点粪便DNA检测在第二轮检测中对结直肠肿瘤具有高阳性预测值
本研究回顾性分析了2758例首轮mt-sDNA阴性、完成第二轮检测的患者,第二轮阳性率为15%,对结直肠癌、进展期前驱病变和任何结直肠肿瘤的阳性预测值分别为0.25%、24%和67%。第二轮与第一轮对进展期前驱病变的阳性预测值无显著差异(24% vs 28%,P=0.12)。
要点
- 第二轮mt-sDNA阳性率为15%,对任何结直肠肿瘤的阳性预测值为67%。
- 第二轮对进展期前驱病变的阳性预测值为24%,与第一轮28%无显著差异。
- 第二轮对结直肠癌的阳性预测值为0.25%。
核心结论
- mt-sDNA检测阳性率和阳性预测值在第一轮与第二轮筛查之间相似。
- 这些观察结果证实了第二轮mt-sDNA筛查的效用,并可能为mt-sDNA用于结直肠癌筛查的效果估计提供信息。
研究设计与样本
- 回顾性研究,纳入首轮mt-sDNA筛查阴性、第二轮筛查阳性的患者,复习结肠镜和病理报告。
- 共2758例患者完成了第二轮检测,中位检测间隔为3.2年。
- 计算第二轮mt-sDNA对结直肠癌、进展期前驱病变和任何结直肠肿瘤的检测阳性率和阳性预测值,并与本机构先前发表的首次筛查阳性队列的基线阳性预测值比较。
主要发现
- 2758例完成第二轮检测的患者中,422例(15%)第二轮mt-sDNA阳性。
- 第二轮阳性预测值:结直肠癌0.25%,进展期前驱病变24%,任何结直肠肿瘤67%。
- 第二轮与第一轮对进展期前驱病变的阳性预测值无显著差异(24% vs 28%,P=0.12)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Multitarget stool DNA (mt-sDNA) testing is a stool-based screening test for colorectal cancer (CRC). In a single instance of testing, the pivotal Food and Drug Administration-approval study (NCT01397747) found that 16% of mt-sDNA tests were positive, and the positive predictive value (PPV) for CRC or advanced precursor lesions (APL) was 27.3%. We aimed to examine real-world longitudinal performance by determining the test-positive rate and PPV of mt-sDNA on the second round of testing. METHODS: Colonoscopy and pathology reports were reviewed retrospectively for patients with a negative mt-sDNA on the first round of screening and a positive mt-sDNA on the second round. The test-positivity rate and PPV for CRC, APL, and any colorectal neoplasia were calculated for the second mt-sDNA and compared with baseline PPVs from a previously published cohort of patients from our institution who tested positive on the first round of screening. RESULTS: A total of 2758 patients completed a second test at a median of 3.2 years after the first test. Of these, 422 (15%) had a positive second mt-sDNA. The PPV was 0.25% for CRC, 24% for APL, and 67% for any colorectal neoplasia. There was no significant difference in PPV on the second mt-sDNA test compared with the first round (24% vs 28% for APL; P = .12). CONCLUSIONS: mt-sDNA test positive rate and PPV were similar between the first and second rounds of screening. These observations confirm the utility of a second round of mt-sDNA screening and may inform estimates of mt-sDNA effectiveness for CRC screening.
引用
- Voss JK, Ebner DW, Burger KN, et al. Multitarget Stool DNA Testing Has High Positive Predictive Value for Colorectal Neoplasia on the Second Round of Testing. Clin Gastroenterol Hepatol. 2023. PMID: 36621751. doi:10.1016/j.cgh.2022.12.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。